Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05394103

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05394103. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

Study identification

NCT ID: NCT05394103
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Qurient Co., Ltd.; Industry
Enrollment: 130 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 30, 2022 (Actual)
Primary completion: Mar 31, 2029 (Estimated)
Completion: Aug 31, 2029 (Estimated)
Last update posted: Nov 9, 2026

2022 – 2029

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Mayo Clinic	Phoenix	Arizona	85054	Recruiting
University of Southern California	Los Angeles	California	90033	Recruiting
Mayo Clinic	Jacksonville	Florida	32224	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
Atlantic Health System Hospital	Morristown	New Jersey	07960	Recruiting
Mary Crowley Cancer Research	Dallas	Texas	75230	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05394103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 9, 2026 · Synced Nov 14, 2026